PharmaTher
Expands Patent Portfolio with Filing of U.S. Patent Application for
Ketamine and Repurposing
of
Psychedelics with panaceAI™
TORONTO,
April
27,
2021 --
InvestorsHub NewsWire -- PharmaTher Holdings Ltd. (the
"Company" or "PharmaTher") (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical
company, today announced that it has filed a provisional patent
application with the U.S. Patent and Trademark Office
outlining the
novel
use of ketamine as a potential treatment for Type 2 diabetes and
obesity, based on the evaluation of
the Company's drug
repurposing artificial intelligence ("AI") platform,
panaceAI™.
PharmaTher
is also
advancing research
with panaceAI™ to
evaluate
repurposing
opportunities with
N,N-Dimethyltryptamine ("DMT"), 3,4-Methylenedioxymethamphetamine
("MDMA") and lysergic acid diethylamide ("LSD") for future clinical
development and partnering opportunities.
The
patent application, entitled "Use of Ketamine in the Treatment of
Diabetes and Obesity," identifies protein bindings and interactions
with ketamine leading to the discovery of ketamine as a potential
treatment for Type 2 diabetes and obesity. The Company has
submitted an Investigational New Drug ("IND") application with the
U.S. Food and Drug Administration ("FDA") for the initiation of a
Phase 2 clinical trial to evaluate ketamine in the treatment of
Parkinson's disease.
Upon
the FDA accepting the IND, PharmaTher will leverage the IND to
expand the clinical development of ketamine in depression,
amyotrophic lateral sclerosis (Lou Gehrig's disease), pain and
obesity-related disorders.
PharmaTher
uses
its drug repurposing AI platform, panaceAI™,
to
expand
on the
Company's patent
portfolio of
novel
uses of
DMT,
MDMA and LSD. PharmaTher's
objective is to
discover novel uses of these psychedelics and incorporate them into
the Company's proprietary microneedle patch delivery system
currently being evaluated at the Terasaki Institute.
The
Company seeks to
commercialize the product developments either internally or partner
with life sciences companies seeking to expand their product
portfolio with psychedelics. PharmaTher recently used panaceAI™ to
discover novel uses of psilocybin in the potential treatment of
certain cancers, which led to the sale of the Company's psilocybin
intellectual property portfolio to
Revive Therapeutics Ltd. (CSE: RVV, OTC: RVVTF) for a consideration of up to CAD $10
million.
Fabio
Chianelli, CEO of PharmaTher, commented:
"We
continue to focus on building our patent and product portfolio
of prescription-based
psychedelics
through our drug repurposing and delivery methods for unmet medical
needs," Fabio Chianelli, CEO of PharmaTher. "Our strategy is to
investigate ketamine in FDA Phase 2 clinical trials for Parkinson's
disease and depression and
with
panaceAI™,
we aim to find new uses of
psychedelics, such as ketamine, psilocybin, DMT, MDMA and LSD, and
incorporate
them
into our proprietary microneedle patch delivery
system.
We are
well-positioned to unlock value in our patent portfolio consisting
of novel uses, formulations and delivery systems for psychedelics
as a pharmaceutical prescription."
About
PharmaTher Holdings Ltd.
PharmaTher Holdings
Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a specialty psychedelic
pharmaceutical
company focused on the research, development and commercialization
of ketamine and novel microneedle patches for the delivery
of psychedelics to
treat neuropsychiatric, neurodegenerative and pain
disorders.
Learn more at:
PharmaTher.com
and follow us on
Twitter
and
LinkedIn.
For
more information about
PharmaTher, please
contact:
Fabio
Chianelli
Chief
Executive Officer
PharmaTher
Holdings
Ltd.
Tel:
1-888-846-3171
Email:
info@pharmather.com
Website:
www.pharmather.com
Neither the Canadian Securities Exchange nor its Regulation
Services Provider have reviewed or accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
This press release contains 'forward-looking information' within
the meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated", "potential", "aim" and similar
expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on PharmaTher Holdings Ltd. (the
"Company") current belief or assumptions as to the outcome and
timing of such future events. Forward-looking information is based
on reasonable assumptions that have been made by the Company at the
date of the information and is subject to known and unknown risks,
uncertainties, and other factors that may cause actual results or
events to differ materially from those anticipated in the
forward-looking information. Given these risks, uncertainties and
assumptions, you should not unduly rely on these forward-looking
statements. The forward-looking information contained in this press
release is made as of the date hereof, and Company is not obligated
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
required by applicable securities laws. The foregoing statements
expressly qualify any forward-looking information contained herein.
Factors that could cause actual results to differ materially from
those anticipated in these forward-looking statements are described
under the caption "Risk Factors" in Company's
management's discussion and analysis for the period of November 30,
2020 ("MD&A"), dated January 27, 2021, which is available on
the Company's profile at
www.sedar.com.
This news release does not constitute an offer to sell or the
solicitation of an offer to buy, and shall not constitute an offer,
solicitation or sale in any state, province, territory or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state, province, territory or
jurisdiction.
